Posted by Michael Wonder on 11 Oct 2022
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma
11 October 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of nivolumab for use in combination with fluoropyrimidine- and platinum-based combination chemotherapy in the NHS in England.
Nivolumab with fluoropyrimidine-based and platinum-based combination chemotherapy is recommended as an option for adults with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma whose tumours express PD-L1 at a level of 1% or more.
It is recommended only if:
- Pembrolizumab plus chemotherapy is not suitable
- BMS provides nivolumab according to the commercial arrangement
